• The Journal of Korean Medicine
• /
• v.39 no.3
• /
• pp.17-27
• /
• 2018

Objectives: Ukgan-san does not appear in Traditional Korean Medicine classics. However, it has been used in research and clinical applications in Korea. In this paper, we are aiming to examine the records concerned with Ukgan-san to the present, and announce the present usage state in Korea. Methods: We searched and summarized the contents of previous medical books about Ukgan-san. In order to investigate the current status of utilization of Ukgan-san in Korea, a bibliographic database of Korea, a database of clinical researches, and a database of pharmaceuticals of the Korea Food and Drug Administration were searched. Results: As a result of searching Ukgan-san related documents, Ukgan-san has been developed in China (Ming dynasty). However, its clinical application has been expanded by modern Japanese kampo medicine doctors. In Korea, cases of Parkinson's disease, other movement disorders, and psychiatric disorders have been reported, and randomized controlled trials had been done and planned. In addition, some extracts which are consisted of Ukgan-san are also available. Conclusions: In Korea, Ukgan-san has been influenced by Japan and has been used for clinical and research purposes. The utilization rate in Korea is still small, but the utilization rate will increase according to the results of clinical studies.

• The Journal of Internal Korean Medicine
• /
• v.34 no.2
• /
• pp.178-191
• /
• 2013

Objectives : In this study, we made an effort to investigate the protective mechanism of Ukgan-san (UGS) extracts on hypoxia-induced C6 glial cell death. Methods : The cell viability was assessed by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MMT) assay and cell morphological changes were analysed with microscope after staining with crystal violet (CV). Reactive oxygen species (ROS) formation was assessed by flow cytometer after staining with 2'7'-dichlorofluorescein diacetate (DCF-DA). We also analyzed expression of hypoxia-inducible factor-1 alpha (HIF-$1{\alpha}$) and p53, processing of procaspase-3 and procyclic acidic repetitive protein (PARP) by western blot method. Results : We estimated the elevated cell viability by UGS extract on $CoCl_2$-induced C6 glial cells. UGS attenuated $CoCl_2$-induced ROS formation in C6 glial cells and also showed a protective activity compared to antioxidants and exhibited abrogation of LDH-released by $CoCl_2$. UGS suppressed the typical apoptotic cell death markers, caspase-3 and PARP activation. UGS inhibited $CoCl_2$-induced HIF-1${\alpha}$ expression which is known as a major regulator for hypoxia-induced cell death, and suppressed p53 expression. Conclusions : These results suggest that UGS extract contains protective constituents for hypoxia-induced C6 glial cell death.

• Journal of Oriental Neuropsychiatry
• /
• v.30 no.3
• /
• pp.287-293
• /
• 2019

Objectives: The purpose of this study was to report the clinical effectiveness of the complex Korean medicine therapy on a patient with BPSD (Behavioral and Psychological Symptoms of Dementia) due to suspected Alzheimer's disease. Methods: We experienced an age 73 female who complained of a depressive mood, insomnia, and accompanying symptoms such as abnormal behavior. During treatment, the patient received acupuncture and herbal medicine. The clinical effects were evaluated through KGDS (Korean Form of Geriatric Depression Scale) and subjective statements of the patient. Results: After the complex Korean medicine therapy, the treatments ameliorated overall symptoms that the patient complained about. The patient was more positive and slept better after the treatment. No specificities or adverse effects were reported during treatment. Conclusions: This study suggests the possibility of treating patients with BPSD with complex Korean medicine therapy.